Evaluation of a novel medical device for pegfilgrastim administration-Reference-Cited by-同舟云学术

Evaluation of a novel medical device for pegfilgrastim administration

Published:2022-03-29 Issue:5 Volume:113 Page:1763-1770
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Aruga Tomoyuki¹^ORCID,Doihara Hiroyoshi²,Yanagita Yasuhiro³,Ishida Takanori⁴,Yamashita Toshinari⁵,Uehara Kanou⁶,Taira Tetsuhiko⁷,Tsurutani Junji⁸,Takeshita Takashi⁹,Tsuyuki Shigeru¹⁰,Kaneko Koji¹¹,Ohtake Tohru¹²,Yamaguchi Yusuke¹³,Hara Yui¹³,Saji Shigehira¹⁴

Affiliation:

1. Department of Breast Surgery Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

2. Department of Breast and Endocrine Surgery Okayama University Hospital Okayama Japan

3. Department of Breast Oncology Gunma Prefectural Cancer Center Gunma Japan

4. Department of Breast and Endocrine Surgical Oncology Tohoku University Graduate School of Medicine Sendai Japan

5. Department of Breast and Endocrine Surgery Kanagawa Cancer Center Yokohama Japan

6. Department of Surgery Nahanishi Clinic Naha Okinawa Japan

7. Department of Medical Oncology Sagara Hospital Kagoshima City Kagoshima Japan

8. Advanced Cancer Translational Research Institute Showa University Tokyo Japan

9. Department of Breast Surgery Hokkaido University Hospital Sapporo Japan

10. Department of Breast Surgery Osaka Red Cross Hospital Osaka Japan

11. Department of Breast Oncology Niigata Cancer Center Hospital Niigata Japan

12. Department of Breast Surgery, School of Medicine Fukushima Medical University Fukushima Japan

13. Kyowa Kirin Co., Ltd. Tokyo Japan

14. Department of Medical Oncology Fukushima Medical University Fukushima Japan

Funder

Taiho Pharmaceutical

Daiichi Sankyo Company

Eisai

Hitachi

Kyowa Hakko Kirin

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15335

Reference9 articles.

1. Same Day Pegfilgrastim and CHOP Chemotherapy for Non-Hodgkin Lymphoma

2. Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients

3. Phase III Trial Comparing Granulocyte Colony-Stimulating Factor to Leridistim in the Prevention of Neutropenic Complications in Breast Cancer Patients Treated with Docetaxel/Doxorubicin/Cyclophosphamide: Results of the BCIRG 004 Trial

4. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

5. G‐LASTA®Subcutaneous Injection 3.6mg Interview Form. Accessed February 1 2022.https://www.info.pmda.go.jp/go/pack/3399410G1020_1_08/?view=frame&style=XML&lang=ja

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study;YAKUGAKU ZASSHI;2024-09-01

2. Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia;BMC Health Services Research;2023-05-23